Product Reports Resources Pricing Login Book a demo

Moderna Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2010 · IPO 2018

Provides a real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease

Valuation $18B
Revenue $2.10B
Power Law Decacorn$10B+ valuation tier Thoroughbred$100M+ revenue
Featured in
News Blackstone invests $250M in Anagram to cut the pill burden for cystic fibrosis patients May 7, 2026

Investors

20 investors on Moderna Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Flagship Pioneering
Series B+ 19 investors entered at this stage
ArrowMark Partners
Harvard Medical School
Invus
BB Biotech Ventures
RA Capital Management
EDBI
Pictet
Julius Baer Group
Merck KGaA
Wellington Management
Sequoia
Harvard University
Alexion Pharmaceuticals
AstraZeneca
Children’s Hospital Boston
Alexandria Venture Investments
Fidelity Investments
Viking Global Investors
Abu Dhabi Investment Authority

Moderna Therapeutics mafia

Startups founded by Moderna Therapeutics alumni

Former Moderna Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

Lila SciencesEst. 2022
JFJacob FealaUnited States
Signal score97
Fortitude BiomedicinesEst. 2025
Jesse ChenUnited States
Signal score91
Dash BioEst. 2024
ATAnder TallettUnited States
Signal score89
Plasana MedicalEst. 2022
Sébastien BalasFrance
Signal score87
Matter NeuroscienceEst. 2019
Axel BouchonUnited States
Signal score86
DillicoEst. 2024
Flora BinderFrance
Signal score86
Innovac TherapeuticsEst. 2022
Nicholas ValianteUnited States
Signal score68
SmartCellaEst. 2014
Kenneth ChienSweden
Signal score65
Korro BioEst. 2018
Andrew FraleyUnited States
Signal score64
Verve TherapeuticsEst. 2018
Barry TichoUnited States
Signal score64
Tessera TherapeuticsEst. 2018
Noubar AfeyanUnited States
Signal score63
Orbital TherapeuticsEst. 2022
GCGiuseppe CiaramellaUnited States
Signal score62

Book a demo to explore the full alumni network →

Global footprint

Where Moderna Therapeutics has talent and traffic

Workforce by country
35 countries with
team presence
🇺🇸 United States81%
🇵🇱 Poland3.2%
🇨🇭 Switzerland3.1%
🇬🇧 United Kingdom2.7%
🇨🇦 Canada2.3%
Top 5 of 35 shown
Web traffic by country
170K monthly visits
across markets
🇺🇸 United States45%
🇬🇧 United Kingdom8.7%
🇮🇳 India6.4%
🇨🇦 Canada4.5%
🏳️ Korea3.3%
Top 5 markets shown

Talent graph

The shape of Moderna Therapeutics's talent

Dealroom maps Moderna Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

20 standout operatorsDealroom-flagged across the org
57 AI specialistsincl. 15 core researchers
6,240 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Moderna Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$189M patent portfolio · 234 active families

Estimated portfolio value
$189M
1.1% of market cap · 4.2× smaller than top peer BioNTech ($788M)
234 active patent families
Where Moderna Therapeutics innovates BiochemistryBioinformaticsCell biologyMolecular biologyNanoparticle

Where Moderna Therapeutics concentrates vs peers

Each axis is a top-10 topic across Moderna Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Moderna Therapeutics's 5 investments and acquisitions.

Every disclosed deal where Moderna Therapeutics appeared as a backer or acquirer, 2014–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

5 deals across Moderna Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Moderna Therapeutics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        5 of 5 deals

        Market sentiment

        What the market is saying about Moderna Therapeutics

        An AI-synthesized read of the highest-engagement posts about Moderna Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Moderna Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles